Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1745-6215
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) ; volume:21 ; number:1 ; day:7 ; month:5 ; year:2020 ; pages:1-9 ; date:12.2020
Trials ; 21, Heft 1 (7.5.2020), 1-9, 12.2020

Creator
Yamashita, Toshinari
Masuda, Norikazu
Saji, Shigehira
Araki, Kazuhiro
Ito, Yoshinori
Takano, Toshimi
Takahashi, Masato
Tsurutani, Junji
Koizumi, Kei
Kitada, Masahiro
Kojima, Yasuyuki
Sagara, Yasuaki
Tada, Hiroshi
Iwasa, Tsutomu
Kadoya, Takayuki
Iwatani, Tsuguo
Hasegawa, Hiroki
Morita, Satoshi
Ohno, Shinji
Contributor
SpringerLink (Online service)

DOI
10.1186/s13063-020-04341-y
URN
urn:nbn:de:101:1-2020081920295928700650
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Yamashita, Toshinari
  • Masuda, Norikazu
  • Saji, Shigehira
  • Araki, Kazuhiro
  • Ito, Yoshinori
  • Takano, Toshimi
  • Takahashi, Masato
  • Tsurutani, Junji
  • Koizumi, Kei
  • Kitada, Masahiro
  • Kojima, Yasuyuki
  • Sagara, Yasuaki
  • Tada, Hiroshi
  • Iwasa, Tsutomu
  • Kadoya, Takayuki
  • Iwatani, Tsuguo
  • Hasegawa, Hiroki
  • Morita, Satoshi
  • Ohno, Shinji
  • SpringerLink (Online service)

Other Objects (12)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer

Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Related objects